

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

September 22, 2003

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.116
Examining Group 1644
Patent Application
Docket No. SPO-103
Serial No. 09/142,524

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Marianne N. DiBrino, Ph.D.
Art Unit : 1644
Applicants : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama,
Kohsuke Kino
Serial No. : 09/142,524
Filed : September 9, 1998
Confirm. No. : 2300
For : Peptide-Based Immunotherapeutic Agent for Treating Allergic
Diseases

OK to file - 9/22/03
Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. § 1.116

A Petition and Fee for a one-month Extension of Time through and including September 21, 2002, accompanies this Amendment.

In response to the Office Action May 21, 2003, please amend the above-identified application as follows:

SEP-22-2003 MON 12:32 PM SALIWANCHIK, LLOYD & SALIWA FAX NO. 352 372 5800

P. 01

OFFICIAL
RECEIVED
CENTRAL FAX CENTER

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK
A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

SEP 22 2003

Telephone (352) 375-8100
Facsimile (352) 372-5800

TO: Examiner Marianne DiBrino

FROM: Frank C. Eisenschenk, Ph.D.

COMPANY: U.S. Patent Office, Art Unit 1644

DATE: September 22, 2003

FAX NO.: 1-703-872-9306

NO. OF PAGES:
(INCLUDING COVER SHEET)

OK to e-mail 11/19/03

SUBJECT/MESSAGE: U.S. Patent Application Docket No. SPO-103
Peptide-Based Immunotherapeutic Agent for Treating Allergic
Diseases
(Sone, et al.)
Serial No. 09/142,524; Filed September 9, 1998

ATTACHMENT:

Petition and Fee for Extension of Time Under 37 C.F.R. § 1.136(a)
Amendment Under 37 C.F.R. § 1.116

~~THIS IS A DRAFT AMENDMENT FOR~~
~~DISCUSSION PURPOSES ONLY~~

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

J:\SPO1103\Fax2Examiner.doc\DNB\ss